US · Healthcare · Biotechnology
EPS came in at 0.09 against a street estimate of 0.12 — a miss of 25.0%.
Analysts rate Legend Biotech Corp a buy (8 buy, 5 hold, 0 sell out of 13) with an average price target of $45.73.
| Fund | Stake |
|---|---|
| FMR Inc | 14.96% |
| Deerfield Management Co | 4.18% |
| Suvretta Capital Management, LLC | 3.64% |
| Hillhouse Capital Advisors, Ltd. | 3.08% |
| BlackRock Inc | 2.43% |
| Westfield Capital Management Company, L.P. | 2.28% |
| Assenagon Asset Management SA | 1.97% |
| The Goldman Sachs Group Inc | 1.88% |
| Document | Date |
|---|---|
| Current report (6-K) · Q4 2026 HEADLINE NUMBERS • On October 15, 2026, the U.S. FDA cleared Legend Biotech’s Investigational New Drug (IND) application for LB2501. • LB2501 is an | 2026-10-15 |
| Quarterly results (6-K) · Q3 2026 HEADLINE NUMBERS • CARVYKTI® generated approximately $710 million in net trade sales during the quarter ended September 30, 2026. • The sales figure | 2026-10-13 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • Legend Biotech reported five-year follow-up data from CARTITUDE-2 Cohort A, evaluating CARVYKTI in 20 patients with relapsed/refra | 2026-09-25 |
| Current report (6-K) · Q3 2026 OTHER NOTABLE POINTS • Legend Biotech Corporation held its 2026 Annual General Meeting of Shareholders on September 24, 2026. • The Form 6-K reports | 2026-09-24 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • Legend Biotech appointed Ingrid Zhang as Chief Executive Officer and principal executive officer, effective September 15, 2026. • | 2026-09-15 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • Legend Biotech Corporation filed a Form 6-K dated September 14, 2026. • The filing announces an updated clinical pipeline availab | 2026-09-14 |
| Annual report FY2025 (20-F) HEADLINE NUMBERS • Legend Biotech reported for the fiscal year ended December 31, 2025; its financial statements use IFRS, not U.S. GAAP. • The comp | 2026-03-10 |
| Annual report FY2024 (20-F) | 2025-03-11 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Legend Biotech Corp — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.